Focus:
News
-
12 June 2020
Novo Nordisk to acquire Corvidia Therapeutics for $725m
Danish healthcare company Novo Nordisk has signed a definitive agreement to acquire US-based Corvidia Therapeutics, which develops and commercialises therapies for cardio-renal diseases, for an upfront payment of $725m.
-
12 June 2020
PeptiDream and Merck partner to develop Covid-19 therapeutics
Japanese biopharmaceutical firm PeptiDream has partnered with Merck (MSD) to discover and develop new peptide therapeutics which could neutralise SARS-CoV-2, the novel coronavirus that causes Covid-19.
-
11 June 2020
AbbVie inks $750m cancer therapeutics deal with Genmab
AbbVie has entered a collaboration agreement with biotechnology company Genmab to develop and commercialise antibody therapeutics for cancer.
-
11 June 2020
BioNTech to receive up to €100m from EIB for vaccine development
German immunotherapy company BioNTech has signed a €100m debt financing agreement with the European Investment Bank (EIB) for the development of its Covid-19 vaccine candidate, BNT162.
-
11 June 2020
Singapore approves Gilead’s remdesivir to treat Covid-19
Singapore's Health Sciences Authority (HSA) has awarded conditional approval for Gilead Sciences Singapore's experimental antiviral drug remdesivir, under the brand name Veklury, to treat adults with Covid-19.
-
10 June 2020
Panacea Biotec and Refana team up for Covid-19 vaccine
Panacea Biotec has partnered with Refana USA for the development, manufacturing and distribution of a Covid-19 vaccine candidate worldwide.
-
10 June 2020
Fujifilm commits $928m to expand biologics facility in Denmark
Japanese conglomerate Fujifilm has plans to invest approximately $928m to expand its large-scale biologics production facility in Denmark.
-
10 June 2020
Daewoong finds niclosamide effective against Covid-19 in animal tests
South Korea-based Daewoong Pharmaceutical has found that its anti-parasitic drug niclosamide had removed SARS-CoV-2, the novel coronavirus that causes Covid-19, from lungs in animal tests.
-
9 June 2020
AstraZeneca licences Covid-19 antibody candidates from VU
AstraZeneca has licensed six coronavirus-neutralising antibody candidates from Vanderbilt University in the US, with plans to advance two into clinical development to prevent and treat Covid-19.
-
9 June 2020
Innovent Biologics enters drug development deal with Roche
Chinese biopharmaceutical firm Innovent Biologics has entered a strategic research and development partnership with Roche for various cell therapies and bispecific antibodies.
Close
Close
Close
Go Top